Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Replicon platform advances may improve RP vaccine safety and efficacy; leaves open prospective human trials before clinical translation.
The alphavirus replicon technology has been utilized for many years to develop vaccines for both veterinary and human applications. Many developments have been made to the replicon platform recently, resulting in improved safety and efficacy of replicon particle (RP) vaccines. This review provides a broad overview of the replicon technology and safety features of the system and discusses the current literature on RP and replicon-based vaccines.
No takes yet. Share an insight, caveat, or question.
Veen et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: